From Endometriosis to Androgenetic Alopecia: How the PRLR Target Ushers in a New Era of Differentiated Antibody Therapy

Keywords: PRLR, prolactin receptor, endometriosis, androgenetic alopecia, HMI-115, ABS-201, breast cancer, JAK-STAT signaling pathway, antibody therapy

From late 2025 to early 2026, the prolactin receptor (PRLR) target field witnessed two milestone clinical advancements. In December 2025, Absci announced that its AI-designed anti-PRLR antibody ABS-201 had completed the first subject dosing for androgenetic alopecia (AGA), becoming the first anti-PRLR antibody globally to enter clinical stages. Around the same time, HopeMed's HMI-115 received Fast Track designation from the U.S. FDA for endometriosis. Two distinct technological approaches, two entirely different major disease areas—one affecting hundreds of millions of women worldwide with a gynecological disorder, the other impacting over half of men with progressive hair loss—both targeting the same PRLR receptor is a rare phenomenon in target development history.

PRLR is a type I cytokine receptor family transmembrane protein whose endogenous ligand prolactin (PRL) plays broad roles in reproduction, immunity, and metabolism. Traditionally, PRLR has been viewed primarily as a core receptor for mammary gland development and lactation regulation, while tumor research has focused on its overexpression in breast and prostate cancers. However, what has propelled PRLR to the forefront of clinical development are precisely these two non-oncology indications closely related to hormonal regulation and immune microenvironment. Meanwhile, PRLR's antagonistic relationship with the Hippo-YAP pathway in breast cancer and its potential as an antibody-drug conjugate (ADC) target continue to attract industry attention. This article systematically examines PRLR's biological mechanisms and latest clinical translation progress from four dimensions—molecular structure, signal transduction, disease association, and differentiated drug development—providing a comprehensive target reference for biopharmaceutical professionals.

The PRLR gene is located on human chromosome 5p13-14 and produces multiple isoforms through alternative splicing. The three main isoforms are the long form (PRLR-LF, ~598 amino acids), intermediate form (PRLR-IF), and short form (PRLR-SF), whose cytoplasmic domain truncation levels determine their respective signal transduction capabilities. PRLR consists of an extracellular ligand-binding domain, a transmembrane helical region, and an intracellular signal transduction domain, making it a typical member of the type I cytokine receptor superfamily.

When prolactin binds to PRLR, it induces receptor homodimerization, causing conformational changes that allow the cytoplasmic Box 1 region to recruit JAK2 kinase to the receptor's cytoplasmic domain. JAK2 then undergoes autophosphorylation and phosphorylates tyrosine residues on PRLR's cytoplasmic tail. The phosphorylated tyrosine sites recruit STAT5 proteins via SH2 domains. JAK2 further phosphorylates STAT5a's Y694 residue and STAT5b's Y699 residue, activating them to form homo- or heterodimers that translocate to the nucleus and activate transcription of downstream target genes like Bcl-xL and cyclin D1. Beyond the classical JAK2-STAT5 pathway, PRLR can also signal through non-canonical pathways like PI3K/Akt and Ras/Raf/MAPK, playing synergistic roles in cell survival, proliferation, and metabolic regulation.

Recent breakthroughs have been made in studying PRLR mutation signaling functions. Researchers functionally assessed over 300 unannotated germline PRLR non-coding mutation sites, finding that certain variants (e.g., Ile146Leu) are significantly more prevalent in benign breast disease patients, while rare activating variants like Asn492Ile are associated with increased prolactinoma incidence. These findings suggest that PRLR functional variant networks may be important underlying mechanisms for signaling dysregulation across different diseases.

Endometriosis is one of PRLR's most notable indications. Affecting ~10% of reproductive-age women globally, it causes chronic pelvic pain, dysmenorrhea, and infertility. Traditional first-line treatments include oral contraceptives, progestins, or GnRH agonists—the latter suppressing estrogen secretion to alleviate symptoms but causing severe bone density loss and menopausal-like side effects that limit their use. Studies show prolactin and its receptor are overexpressed in ectopic endometrial tissue, where PRLR signaling promotes local inflammation, angiogenesis, and neural sensitization, contributing to endometriosis-related pain. Targeting PRLR may directly block this pathogenic axis without disrupting systemic hormone levels.

Androgenetic alopecia (AGA) is another unexpected yet mechanistically plausible PRLR-related indication. AGA is the most common progressive hair loss type, with male prevalence exceeding 50% with age and significant female incidence. Although androgen and its receptor pathways are central to AGA, preclinical and clinical evidence suggests prolactin signaling also regulates hair follicle cycles. PRLR is expressed in outer root sheath cells, and prolactin can prematurely transition follicles from growth to regression phase, inhibiting hair elongation and promoting loss. Unlike androgen pathway interventions, PRLR-targeted therapy may protect follicles without affecting sex hormone balance, offering a novel AGA treatment option.

Breast cancer remains PRLR's most classic oncology indication. ~40-50% of breast cancer patients exhibit PRLR overexpression, yet its prognostic association is complex. A pivotal 2025 Cell Death & Disease study revealed PRLR's novel antagonistic relationship with the Hippo-YAP pathway. PRL/PRLR signaling exerts pro-differentiation effects in normal mammary epithelial and breast cancer cells, functionally opposing the YAP-CCN2 oncogenic pathway. PRLR expression positively correlates with Hippo pathway YAP suppressors, and its co-expression network drives better patient outcomes. This finding not only provides new differentiation therapy strategies but also explains why early ligand-competitive anti-PRLR antibodies (e.g., LFA102) failed in solid tumors—PRLR's anti-tumor activity likely depends on complex crosstalk with cell fate-determining pathways rather than simple signal blockade.

Current global PRLR-targeted drug development features two clear complementary approaches:

Anti-PRLR antibodies like HMI-115—dual advancement in endometriosis and hair loss. HMI-115, a humanized anti-PRLR monoclonal antibody licensed from Bayer by HopeMed, leads global clinical development. In a completed randomized, placebo-controlled Phase II proof-of-concept trial, surgically confirmed endometriosis patients receiving 240mg biweekly dosing showed profound, durable, and statistically significant improvements in dysmenorrhea and non-menstrual pelvic pain. HMI-115's key differentiation is its estrogen-independent efficacy, avoiding GnRH agonists' bone density loss and menopausal symptoms. Based on these results, the FDA granted HMI-115 Fast Track designation for endometriosis in early 2026. For AGA, HMI-115 has completed Phase I safety evaluation and is advancing to Phase II, with preliminary data showing hair growth promotion trends.

AI-designed antibodies like ABS-201—precision intervention in hair loss. Absci's Integrated Drug Creation™ AI platform de novo designed anti-PRLR antibody ABS-201, which completed first subject dosing for AGA in December 2025, becoming the first anti-PRLR antibody to enter clinical stages globally. AI design optimized ABS-201's pharmacokinetics and developability while maintaining high affinity and selectivity, potentially enabling more convenient dosing. This case also demonstrates generative AI's practical value in accelerating target validation and molecule discovery.

PRLR's potential in ADC and bispecific antibody oncology development. Although simple blocking antibody LFA102 failed in Phase I solid tumor trials, PRLR's high expression in breast and prostate cancers continues attracting ADC interest. Cytotoxic payload conjugation to anti-PRLR antibodies could selectively kill PRLR-positive tumor cells independent of receptor signaling. Multiple preclinical PRLR-ADC programs are underway, and PRLR-targeted bispecific T-cell engagers may expand to PRLR-positive solid tumors.

PRLR's unique value lies in its cross-disease differentiation capability—the same target can unleash clinical potential simultaneously in gynecology, dermatology, and oncology, greatly expanding risk-adjusted development space. Future strategic priorities include: further clarifying PRLR's tissue-specific signaling outputs to guide indication selection and combination strategies; advancing PRLR antibodies toward registrational trials in endometriosis and hair loss for regulatory breakthroughs; exploring PRLR-ADC and bispecific antibodies' precision oncology value; and leveraging AI platforms to accelerate antibody engineering and indication expansion.

The global PRLR-targeted drug market is at a critical transition from concept validation to clinical value realization. With HMI-115 and ABS-201 clinical data readouts, PRLR may become the next receptor target after TNFα and IL-4Rα to achieve cross-indication success in autoimmunity and regenerative medicine.

```